Product Information
GALANTAMINE HBR 4 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.2940 per EA under NDC 57237004960. Its NADAC has been published 652 times since Apr 9, 2014.
FDA first approved this application on Mar 29, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237004960
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GALANTAMINE HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090957FDA Approved
3/29/2011
TE Code
AB
On Market Since
3/29/2011
Pharmacological Classes
Price Statistics
The NADAC for GALANTAMINE HBR 4 MG TABLET has been published 652 times since Apr 9, 2014, and over the history we have for it it has declined 80.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2940 per EA |
|---|---|
| All-time high | $1.5340 (May 14, 2014) |
| All-time low | $0.2164 (May 22, 2024) |
| 52-week high | $0.3421 |
| 52-week low | $0.2687 |
| Median price | $0.5421 |
| Average price | $0.6963 |
| Largest weekly change | +69.4% (Jan 17, 2024) |
| Weeks tracked | 652 |
| Tracking since | Apr 9, 2014 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Galantamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GALANTAMINE HBR 4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GALANTAMINE HBR 4 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.2940 per EA (NDC 57237004960), effective Sep 30, 2026.
How has the price of GALANTAMINE HBR 4 MG TABLET changed over time?
Over the history we have for it, the NADAC for GALANTAMINE HBR 4 MG TABLET has declined 80.8%. It has been tracked across 652 weekly CMS publications since Apr 9, 2014.
What are the highest and lowest recorded NADAC prices for GALANTAMINE HBR 4 MG TABLET?
Since Apr 9, 2014, the NADAC for GALANTAMINE HBR 4 MG TABLET has ranged from a low of $0.2164 (May 22, 2024) to a high of $1.5340 (May 14, 2014), with a median of $0.5421 per EA.
Are there cheaper alternatives to GALANTAMINE HBR 4 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GALANTAMINE HBR 4 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures GALANTAMINE HBR 4 MG TABLET?
GALANTAMINE HBR 4 MG TABLET (NDC 57237004960) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.